Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?
European Journal of Cancer · 2026-12 · 249 · 117808
DOI: 10.1016/j.ejca.2026.117808 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-12. Verfasst von Patrick Neven und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.
- Department of Medical Oncology, University Hospitals Saint-Luc, UC Louvain, Brussels, Belgium.
- Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium.
- Breast Clinic, AZ Sint-Maarten, Mechelen, Belgium.
- Department of Oncology, AZ Turnhout, Turnhout, Belgium.
- Department of Oncology, Jan Yperman Ziekenhuis, Ieper, Belgium.
Zitieren
APA
Neven, P., Duhoux, F., Aftimos, P., Berteloot, P., de Azambuja, E., De Backer, C., Debaere, D., Derouane, F., Fontaine, C., Han, S., Huygh, G., Ignatiadis, M., Naert, E., Punie, K., Requilé, A., Sotiriou, C., Tjalma, W., Traen, K., Van Herck, Y., & Wildiers, H. (2026). Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?. European Journal of Cancer, 249, 117808. https://doi.org/10.1016/j.ejca.2026.117808
Vancouver
Neven P, Duhoux F, Aftimos P, Berteloot P, de Azambuja E, De Backer C, et al. Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?. European Journal of Cancer. 2026;249:117808. doi:10.1016/j.ejca.2026.117808
BibTeX
@article{Neven2026,
author = {Neven, Patrick and Duhoux, Francois and Aftimos, Philippe and Berteloot, Patrick and de Azambuja, Evandro and De Backer, Cleo and Debaere, Debbie and Derouane, Françoise and Fontaine, Christel and Han, Sileny and Huygh, Greet and Ignatiadis, Michail and Naert, Eline and Punie, Kevin and Requilé, Annelies and Sotiriou, Christos and Tjalma, Wiebren and Traen, Koen and Van Herck, Yannick and Wildiers, Hans},
title = {Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?},
journal = {European Journal of Cancer},
year = {2026},
volume = {249},
pages = {117808},
doi = {10.1016/j.ejca.2026.117808}
}
EUVIMED